GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (NAS:ASND) » Definitions » Shiller PE Ratio

ASND (Ascendis Pharma AS) Shiller PE Ratio : (As of Mar. 14, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma AS Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS Shiller PE Ratio Historical Data

The historical data trend for Ascendis Pharma AS's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Shiller PE Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ascendis Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascendis Pharma AS's Shiller PE Ratio

For the Biotechnology subindustry, Ascendis Pharma AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Shiller PE Ratio falls into.



Ascendis Pharma AS Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ascendis Pharma AS's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Ascendis Pharma AS's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.67/118.9000*118.9000
=-0.670

Current CPI (Dec. 2024) = 118.9000.

Ascendis Pharma AS Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 0.065 100.200 0.077
201506 -0.707 100.300 -0.838
201509 -0.337 100.200 -0.400
201512 -0.534 99.800 -0.636
201603 -0.913 100.200 -1.083
201606 -0.596 100.600 -0.704
201609 -0.808 100.200 -0.959
201612 -0.538 100.300 -0.638
201703 -0.834 101.200 -0.980
201706 -1.056 101.200 -1.241
201709 -1.240 101.800 -1.448
201712 -1.089 101.300 -1.278
201803 -1.319 101.700 -1.542
201806 -0.643 102.300 -0.747
201809 -0.945 102.400 -1.097
201812 -0.865 102.100 -1.007
201903 -1.401 102.900 -1.619
201906 -1.412 102.900 -1.632
201909 -0.584 102.900 -0.675
201912 -1.889 102.900 -2.183
202003 -1.459 103.300 -1.679
202006 -2.218 103.200 -2.555
202009 -2.721 103.500 -3.126
202012 -3.212 103.400 -3.693
202103 -1.393 104.300 -1.588
202106 -3.012 105.000 -3.411
202109 -1.729 105.800 -1.943
202112 -2.113 106.600 -2.357
202203 -2.434 109.900 -2.633
202206 -1.543 113.600 -1.615
202209 -3.000 116.400 -3.064
202212 -3.919 115.900 -4.020
202303 -2.120 117.300 -2.149
202306 -2.340 116.400 -2.390
202309 -3.074 117.400 -3.113
202312 -1.679 116.700 -1.711
202403 -2.500 118.400 -2.511
202406 -2.056 118.500 -2.063
202409 -1.909 118.900 -1.909
202412 -0.670 118.900 -0.670

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS  (NAS:ASND) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ascendis Pharma AS Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.